Related Experiment Videos
Antagonists selective for NMDA receptors containing the NR2B subunit
1Central Research Division, Pfizer Inc., Groton, CT 06340, USA. chenab@pfizer.com
Current Pharmaceutical Design
|April 24, 1999
Summary
Ifenprodil selectively targets N-methyl-D-aspartate (NMDA) receptors containing the NR2B subunit. This selectivity offers potential for improved therapeutic safety in treating neurological conditions.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- N-methyl-D-aspartate (NMDA) receptors are crucial in synaptic plasticity and neuronal function.
- Early NMDA receptor antagonists lacked selectivity, leading to side effects.
Purpose of the Study:
- To review the structure-activity relationships (SAR) of NR2B-selective NMDA receptor antagonists.
- To explore the therapeutic potential of these selective agents.
Main Methods:
- Identification and expression of NMDA receptor subunits.
- Functional studies in various brain regions.
- Development of structure-activity relationships (SAR) for NR2B antagonists.
Main Results:
- Ifenprodil identified as a selective antagonist for NMDA receptors containing the NR2B subunit.
- NR2B subunit identification was key to understanding ifenprodil's mechanism.
- SAR studies revealed compounds with improved selectivity profiles.
Conclusions:
- NR2B-selective NMDA receptor antagonists represent a promising therapeutic strategy.
- Selectivity for NR2B may offer an improved clinical safety profile over non-selective agents.